Golden State Equity Partners Makes New Investment in Hologic, Inc. $HOLX

Key Points

• Golden State Equity Partners has initiated a new investment in Hologic, Inc., acquiring 6,285 shares valued at approximately $410,000 during Q2.
• Wall Street analysts are optimistic about Hologic, with notable upgrades from Morgan Stanley and Argus, setting a range of price targets up to $90.00.
• CEO Stephen P. Macmillan sold a significant number of shares, totaling over $9 million, reducing his position in the company by 10.08%.

Golden State Equity Partners purchased a new position in Hologic, Inc. (NASDAQ:HOLX - Free Report) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 6,285 shares of the medical equipment provider's stock, valued at approximately $410,000.

Other institutional investors have also added to or reduced their stakes in the company. Zions Bancorporation National Association UT bought a new position in Hologic in the first quarter worth approximately $34,000. Allworth Financial LP raised its position in Hologic by 46.0% in the first quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider's stock worth $40,000 after acquiring an additional 216 shares during the period. Bank Julius Baer & Co. Ltd Zurich bought a new position in Hologic in the first quarter worth approximately $42,000. Larson Financial Group LLC raised its position in Hologic by 6,016.7% in the first quarter. Larson Financial Group LLC now owns 734 shares of the medical equipment provider's stock worth $45,000 after acquiring an additional 722 shares during the period. Finally, West Financial Advisors LLC bought a new position in Hologic in the first quarter worth approximately $50,000. 94.73% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the stock. Morgan Stanley increased their price target on shares of Hologic from $65.00 to $69.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 31st. Needham & Company LLC reissued a "hold" rating on shares of Hologic in a research note on Tuesday, May 27th. Argus increased their price objective on shares of Hologic from $80.00 to $90.00 and gave the stock a "buy" rating in a research note on Friday, September 19th. Stephens reissued an "overweight" rating and issued a $78.00 price objective on shares of Hologic in a research note on Thursday, September 18th. Finally, Royal Bank Of Canada raised shares of Hologic from a "sector perform" rating to an "outperform" rating and increased their price objective for the stock from $72.00 to $87.00 in a research note on Wednesday, August 6th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and eight have assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $79.38.

Hologic Price Performance

HOLX stock opened at $67.64 on Wednesday. Hologic, Inc. has a 52 week low of $51.90 and a 52 week high of $84.39. The company has a quick ratio of 2.81, a current ratio of 3.55 and a debt-to-equity ratio of 0.52. The company has a fifty day simple moving average of $66.61 and a two-hundred day simple moving average of $62.81. The firm has a market capitalization of $15.04 billion, a P/E ratio of 28.07, a price-to-earnings-growth ratio of 2.44 and a beta of 0.57.

Hologic (NASDAQ:HOLX - Get Free Report) last released its quarterly earnings data on Wednesday, July 30th. The medical equipment provider reported $1.08 EPS for the quarter, beating the consensus estimate of $1.05 by $0.03. The business had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.01 billion. Hologic had a net margin of 13.79% and a return on equity of 19.69%. Hologic's quarterly revenue was up 1.2% compared to the same quarter last year. During the same quarter last year, the business earned $1.06 earnings per share. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. Analysts anticipate that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Insider Activity

In other news, CEO Stephen P. Macmillan sold 138,358 shares of the firm's stock in a transaction dated Monday, September 22nd. The shares were sold at an average price of $66.97, for a total value of $9,265,835.26. Following the completion of the sale, the chief executive officer owned 1,234,624 shares in the company, valued at approximately $82,682,769.28. This trade represents a 10.08% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 1.88% of the company's stock.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.